CN1914214A - 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途 - Google Patents

三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途 Download PDF

Info

Publication number
CN1914214A
CN1914214A CNA2004800416435A CN200480041643A CN1914214A CN 1914214 A CN1914214 A CN 1914214A CN A2004800416435 A CNA2004800416435 A CN A2004800416435A CN 200480041643 A CN200480041643 A CN 200480041643A CN 1914214 A CN1914214 A CN 1914214A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
amino
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800416435A
Other languages
English (en)
Chinese (zh)
Inventor
萨莉·雷德肖
伊曼纽尔·H·德蒙特
达里尔·S·沃尔特
戴维·R·维西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1914214A publication Critical patent/CN1914214A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2004800416435A 2003-12-12 2004-12-09 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途 Pending CN1914214A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0328900.6 2003-12-12
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds

Publications (1)

Publication Number Publication Date
CN1914214A true CN1914214A (zh) 2007-02-14

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800416435A Pending CN1914214A (zh) 2003-12-12 2004-12-09 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途

Country Status (17)

Country Link
US (1) US20070073060A1 (https=)
EP (1) EP1692143B1 (https=)
JP (1) JP2007513913A (https=)
KR (1) KR20060121164A (https=)
CN (1) CN1914214A (https=)
AT (1) ATE414090T1 (https=)
AU (1) AU2004299231A1 (https=)
BR (1) BRPI0417476A (https=)
CA (1) CA2549072A1 (https=)
DE (1) DE602004017777D1 (https=)
GB (1) GB0328900D0 (https=)
IL (1) IL175819A0 (https=)
IS (1) IS8521A (https=)
MA (1) MA28241A1 (https=)
NO (1) NO20063137L (https=)
RU (1) RU2006124863A (https=)
WO (1) WO2005058915A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050239836A1 (en) 2004-03-09 2005-10-27 Varghese John Substituted hydroxyethylamine aspartyl protease inhibitors
EP1773756A2 (en) 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
BRPI0515383A (pt) * 2004-09-21 2008-07-22 Pfizer Prod Inc n-etil hidroxietilamina útil no tratamento de condições do snc
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
PT2185561E (pt) * 2007-07-27 2011-09-07 Sanofi Aventis Derivados de 1,2,3,4-tetra-hidropirrolo(1,2-a)pirazina-6- carboxamidas e de 2,3,4,5-tetra-hidropirrolo(1,2-a)-diazepina-7- carboxamidas, sua preparação e sua aplicação em terapia
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
EP2310019A4 (en) * 2008-05-29 2011-06-01 Albany Molecular Res Inc 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CN104768949A (zh) * 2012-08-24 2015-07-08 特温蒂斯公司 苯并呋咱抗淀粉样蛋白化合物和方法
US12043631B2 (en) 2017-10-13 2024-07-23 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease
WO2019075358A1 (en) * 2017-10-13 2019-04-18 Ghosh Arun K BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
NZ533107A (en) * 2001-11-08 2007-04-27 Upjohn Co N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
IL175819A0 (en) 2006-10-05
KR20060121164A (ko) 2006-11-28
BRPI0417476A (pt) 2007-05-08
AU2004299231A1 (en) 2005-06-30
EP1692143A1 (en) 2006-08-23
IS8521A (is) 2006-06-26
DE602004017777D1 (de) 2008-12-24
CA2549072A1 (en) 2005-06-30
EP1692143B1 (en) 2008-11-12
NO20063137L (no) 2006-08-31
RU2006124863A (ru) 2008-01-20
WO2005058915A1 (en) 2005-06-30
ATE414090T1 (de) 2008-11-15
US20070073060A1 (en) 2007-03-29
JP2007513913A (ja) 2007-05-31
GB0328900D0 (en) 2004-01-14
MA28241A1 (fr) 2006-10-02

Similar Documents

Publication Publication Date Title
CN1914214A (zh) 三环吲哚羟乙基胺衍生物和它们在治疗阿尔茨海默病中的用途
CN1094929C (zh) 乙酰胺衍生物,其制备方法,及含该衍生物的药物组合物
CN1205207C (zh) 取代的吲哚链烷酸
MXPA05006088A (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
CN1809573A (zh) 三环吲哚衍生物和它们在治疗阿尔茨海默病中的用途
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1551881A (zh) 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1646529A (zh) 咪唑并稠合化合物
CN1714093A (zh) 二嗪并嘧啶类
CN1688557A (zh) 用于治疗神经变性疾病的噻唑化合物
CN1291095A (zh) 化学化合物
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1812992A (zh) Hiv整合酶抑制剂
CN1845914A (zh) 用于治疗眼压过高的眼用组合物
CN1022322C (zh) 稠合吡唑3-氧代-丙腈衍生物的制备方法
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1794985A (zh) 氮杂双环衍生物作为毒蕈碱受体拮抗剂
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1552714A (zh) 2-取代苯基-5，7-二烃基-3，7-二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其药物用途
CN1282643C (zh) 用于制备具有5－羟色胺－2受体拮抗作用和α1－阻断作用的化合物的中间体及其制法
CN1085550A (zh) 作为人类免疫缺乏病毒逆转录酶抑制剂的新的喹唑啉类
CN1993367A (zh) 稠合的嘧啶衍生物和黄嘌呤氧化酶抑制剂
CN1145617A (zh) 吲哚衍生物及含它们的药物
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN1729191A (zh) 具有免疫调制活性的吡唑并喹啉

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication